Nautilus Biotechnology, Inc.
NAUT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $24 | $34 | $33 | $28 |
| Short-Term Investments | $108 | $113 | $106 | $102 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $3 | $3 | $3 |
| Total Curr. Assets | $134 | $151 | $142 | $133 |
| Property Plant & Equip (Net) | $28 | $30 | $31 | $32 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $37 | $32 | $54 | $76 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $67 | $62 | $86 | $110 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $201 | $213 | $228 | $243 |
| Liabilities | – | – | – | – |
| Payables | $1 | $1 | $1 | $1 |
| Short-Term Debt | $4 | $4 | $4 | $4 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $4 | $3 | $3 | $3 |
| Total Curr. Liab. | $9 | $8 | $8 | $8 |
| LT Debt | $23 | $24 | $25 | $26 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $23 | $24 | $25 | $26 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $23 | $28 | $29 | $30 |
| Total Liabilities | $32 | $32 | $33 | $34 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$318 | -$305 | -$290 | -$273 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $487 | $486 | $484 | $482 |
| Total Equity | $169 | $181 | $194 | $209 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $201 | $213 | $228 | $243 |
| Net Debt | $3 | -$6 | -$4 | $3 |